Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
ALLO Stock Chart & Stats
$2.39
-$0.03(-1.28%)
At close: 4:00 PM EST
$2.39
-$0.03(-1.28%)
Day’s Range― - ―
52-Week Range$0.86 - $4.46
Previous CloseN/A
Volume1.66M
Average Volume (3M)12.66M
Market Cap
$712.25M
Enterprise Value$582.71M
Total Cash (Recent Filing)$250.21M
Total Debt (Recent Filing)$83.25M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
May 06, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding331,277,920
10 Day Avg. Volume26,863,255
30 Day Avg. Volume12,663,847
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.61
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$8.71Price Target Upside264.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$13.85K
Bulls Say, Bears Say
Bulls Say
Commercial Outlook And Analyst ConfidenceAnalyst increases in approval probability, expected market penetration, and valuation, together with a reiterated Buy, reflect confidence that cema‑cel could capture a sizable commercial opportunity if approvals are received and manufacturing scales.
Efficacy - MRD ConversionHigher rates of minimal residual disease (MRD) negativity in the ALPHA3 trial reduce the risk of missing the primary event‑free survival endpoint and suggest a greater chance of meaningful clinical benefit.
Safety And TolerabilityReported absence of severe cytokine release syndrome, neurotoxicity, graft‑versus‑host disease, and serious infections for cema‑cel supports a favorable safety profile that could enable broader use in community cancer centers.
Bears Say
Durability RiskRisk that the therapy’s clinical benefit may not be durable could undermine long‑term value even if early MRD and ctDNA responses appear strong.
Financing And DilutionA planned public offering of common stock would raise cash but may dilute existing shareholders and pressure near‑term capital structure and share performance.
Regulatory And Timeline RiskRegulators requesting additional progression‑based data or more events for approval could delay timelines and postpone commercialization milestones.
Allogene Therapeutics News
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $0.86 and its highest was $4.46 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Allogene Therapeutics Inc’s market cap is $712.25M.
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is May 06, 2026 which is tomorrow.
How were Allogene Therapeutics Inc’s earnings last quarter?
Allogene Therapeutics Inc released its earnings results on Mar 12, 2026. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.226 by $0.056.
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -0.19.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 331,277,920 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Allogene Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.226. Following the earnings report the stock price went down -2.834%.
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Currently, no hedge funds are holding shares in ALLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Allogene Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.71 (264.59% Upside)
$8.71 (264.59% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 151.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 34.1%
Last 30 Days ▲ 34.1%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.82%
12-Months-Change
Fundamentals
Return on Equity
-57.07%
Trailing 12-Months
Asset Growth
-24.20%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
ALLO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple high-impact near-term catalysts (April MRD readout for ALPHA-3 and June proof-of-concept data for ALLO-329), a differentiated autoimmune approach with potential low/no lymphodepletion, and an extended cash runway into 2028 to support prioritized programs. However, the company faces meaningful financial losses, dependence on surrogate MRD endpoints with incomplete linkage to clinical outcomes, competitive headwinds from frontline bispecifics, and uncertainty around safety and small-sample interim analyses. On balance, the call emphasized execution readiness and funding to reach key inflection points while acknowledging important clinical and market risks.View all ALLO earnings summariesALLO Stock 12 Month Forecast
Average Price Target
$8.71
▲(264.59% Upside)
Technical Analysis
Abeona Therapeutics
―
―
Foghorn Therapeutics
―
Tenaya Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
6.95% Insiders
8.28% Mutual Funds
2.28% Other Institutional Investors
74.43% Public Companies and
Individual Investors